Docoh
Loading...

KYMR Kymera Therapeutics

News

From Benzinga Pro
Kymera Therapeutics Q3 EPS $(0.56) Down From $(0.39) YoY, Sales $20.34M Up From $14.53M YoY
10 Nov 21
Earnings, News
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.56) per share. This is a 43.59 percent decrease over losses of $(0.39) per share from the same period last year. The company reported $20.34 million in
Kymera Therapeutics To Present New Preclinical Data On STAT3 Degraders At The Society For Immunotherapy Of Cancer's 36th Annual Meeting And The 63rd American Society Of Hematology Annual Meeting
4 Nov 21
Biotech, News, Events, General
Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the
Kymera Therapeutics To Host Webcast To Discuss Data From Its KT-474 Phase 1 Trial Oct. 27 At 10:30 a.m. EDT
20 Oct 21
News, Events
Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the
Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation Summit
13 Oct 21
News, Events
Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the
Where Kymera Therapeutics Stands With Analysts
30 Sep 21
Analyst Ratings
Over the past 3 months, 5 analysts have published their opinion on Kymera Therapeutics (NASDAQ:KYMR) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
30 Sep 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
B. Riley Securities Initiates Coverage On Kymera Therapeutics with Neutral Rating, Announces Price Target of $67
30 Sep 21
News, Price Target, Initiation, Analyst Ratings
B. Riley Securities analyst Kalpit Patel initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Neutral rating and announces Price Target of $67.
Stifel Initiates Coverage On Kymera Therapeutics with Buy Rating, Announces Price Target of $80
30 Sep 21
News, Price Target, Initiation, Analyst Ratings
Stifel analyst Bradley Canino initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Buy rating and announces Price Target of $80.
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
17 Sep 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16)
B of A Securities Upgrades Kymera Therapeutics to Buy, Raises Price Target to $80
10 Sep 21
News, Upgrades, Price Target, Analyst Ratings
B of A Securities analyst Geoff Meacham upgrades Kymera Therapeutics (NASDAQ:KYMR) from Neutral to Buy and raises the price target from $65 to $80.

Press releases

From Benzinga Pro
Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
12 Nov 21
News, Press Releases
WATERTOWN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule
Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update
10 Nov 21
Earnings, Press Releases
Proof-of-mechanism and proof-of-biology established for first-in-class, oral IRAK4 degrader, KT-474, in Single Ascending Dose portion of Phase 1 healthy volunteer trial with up to 96% degradation in blood and up to 97%
Kymera Therapeutics to Participate in Upcoming Fourth Quarter Investor Conferences
1 Nov 21
News, Press Releases
WATERTOWN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein
Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation Summit
13 Oct 21
Health Care, Press Releases
WATERTOWN, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule
Kymera Therapeutics to Present at Upcoming September Investor Conferences
2 Sep 21
News, Press Releases
WATERTOWN, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein